TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05952817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical Exercise
Description: Rehabilitation program of exercise
Study: NCT05340075

Intervention type: PROCEDURE
Intervention: Patients who underwent percutaneous nephrolithotomy
Description: Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation

Intervention type: PROCEDURE
Intervention: Patients who underwent percutaneous nephrolithotomy
Description: Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
Study: NCT05832801

Intervention type: OTHER
Group type: OTHER
Intervention: ( Traditional dietary advice )
Description: traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ( Traditional dietary advice )
Description: traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Pilates exercises)
Description: Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
Study: NCT05397886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
Study: NCT05790811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician-oriented Video
Description: previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-oriented video
Description: The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council.
Study: NCT05284578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassionate writing intervention
Description: Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Description: Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control writing task
Description: Participants assigned to this condition were asked to engage in a neutral time management writing task.
Study: NCT06015529

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4PEPS strategy
Description: Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~1. based only on clinical data (very low CP: PEPS \< 0),~2. based on a D-dimer level \< 1000 μg/L (low CP: PEPS ≥ 0 and \< 5),~3. based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and \<12), or~4. the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)
Study: NCT06002113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOCD Tool
Description: Web-based tool with 4 components; pre-admission health status; current illness prognosis for hospital survival; in-hospital cardiorespiratory arrest prognosis; values and goals of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Attending physicians responsible for GOCD during hospitalization using their usual approaches
Study: NCT06193928

Intervention type: DRUG
Intervention: Maralixibat
Description: The recommended dosage is 380 mcg/kg once daily.
Study: NCT05998395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
Study: NCT05825469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Algorithm
Description: A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
Study: NCT06175455

Intervention type: DEVICE
Intervention: dynamic chest radiography
Description: A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images

Intervention type: DEVICE
Intervention: dynamic chest radiography
Description: A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
Study: NCT05864755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+Durvalumab+Tremelimumab+Bevacizumab
Description: Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
Study: NCT06134752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse field ablation
Description: Point by point isolation of pulmonary veins and left atrial posterior wall

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Point by point isolation of pulmonary veins and left atrial posterior wall
Study: NCT05759078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin \<100 ng/mL or/and TSAT \<20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
Study: NCT04239859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet up to 15mg per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: Oral capsule up to 200mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Oral capsule up to 25mg per day
Study: NCT05235451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-Animal Interactions
Description: Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
Study: NCT04569903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer algorithm for ATTR
Description: Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
Study: NCT05438329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1305/BNT325
Description: Administered Injection of Vein (I.V.)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered I.V.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.
Study: NCT06180720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
Study: NCT05438329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Administered I.V.
Study: NCT06180720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Study: NCT04526860

Intervention type: OTHER
Group type: OTHER
Intervention: Calibration of infant breast milk and formula milk intake
Description: We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
Study: NCT04763785

Intervention type: DEVICE
Intervention: Corneal tomography with Eyestar 900
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas

Intervention type: DEVICE
Intervention: Corneal tomography with Eyestar 900
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas

Intervention type: DEVICE
Intervention: Corneal tomography with Pentacam
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas

Intervention type: DEVICE
Intervention: Corneal tomography with Pentacam
Description: Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas

Intervention type: DEVICE
Intervention: Biometry with IOL-Master
Description: Non-invasive biometry for presurgical intraocular lens calculation

Intervention type: DEVICE
Intervention: Biometry with IOL-Master
Description: Non-invasive biometry for presurgical intraocular lens calculation

Intervention type: OTHER
Intervention: retrospective analysis, no intervention
Description: retrospective analysis of 4500 existing, fully anonymised picture data
Study: NCT04636073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study: NCT04123704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: sitravatinib capsule
Study: NCT05841667

Intervention type: DRUG
Intervention: Remimazolam besylate
Description: This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam.
Study: NCT05426707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-RIC
Description: The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
Study: NCT05553613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
Study: NCT05498337

Intervention type: OTHER
Group type: OTHER
Intervention: calcium hydroxide
Description: Dental pulp medicament material

Intervention type: OTHER
Group type: OTHER
Intervention: MTA
Description: Dental pulp medicament material

Intervention type: DEVICE
Group type: OTHER
Intervention: Diode Laser
Description: Device used in pulp therapy
Study: NCT05661461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
Study: NCT04972331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Partial Meniscectomy
Description: Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platet- Rich-Plasma
Description: Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-intervention
Description: All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-intervention
Description: All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
Study: NCT06472180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ceramic sectional veneer
Description: partial laminate veneer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ceramic laminate veneer
Description: Glass ceramic laminate veneer
Study: NCT05263284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloroadenosine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05274048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Pill
Description: Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Description: standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
Study: NCT04768296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
Study: NCT06573801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aktiia Bracelet
Description: Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healthstats BPro Evo
Description: Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spacelabs OnTrak Ambulatory Blood Pressure monitor
Description: Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spacelabs OnTrak Ambulatory Blood Pressure monitor
Description: Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
Study: NCT04826341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.